Lausanne, November 21, 2024 - Leman Biotech, a clinical-stage biotechnology company specializing in the development, production, and commercialization of innovative metabolic immunotherapies, has been selected to deliver both oral and poster presentations at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. The ASH Annual Meeting is the world's largest and most comprehensive hematology conference, taking place this year from December 7–10, 2024, in San Diego, California.
Leman Biotech will present clinical results from its first-in-human, investigator-initiated clinical trials for Metabolically Armed CD19 CAR-T Cell Therapy for relapsed or refractory B-cell hematological malignancies. The investigator of the clinical trial, Dr. Yongxian Hu, from the First Affiliated Hospital of Zhejiang University School of Medicine, will deliver the oral presentation. Leman Biotech’s Associate Director of R&D, Dr. Jingjing Ren, will also attend the meeting.
In the first half of this year, Leman Biotech successfully helped over 20 patients achieve complete remission (CR) in investigator-initiated clinical trials (IIT) using extremely low doses of CAR-T cells—just 1% of the standard dose.
Notably, since the second half of the year, Leman Biotech’s R&D team, in close collaboration with clinical experts, has achieved new breakthroughs in clinical research. In the latest IIT study, the injection dose of metabolically armed CAR-T cells was further reduced to an astonishing 0.1% (1‰) of the standard dose. Remarkably, even at such a minuscule dose, the CAR-T cells expanded efficiently within patients' bodies, enabling several to achieve complete remission (CR) while significantly reducing their hospital stays.
Details of the oral presentation:
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: CAR-T Cell Therapies for Lymphomas and ALL: New Strategies and Toxicities
92: IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies
Session Time: Saturday, Dec. 7, 2024 9:30 AM - 11:00 AM
Presentation Time: 9:45 AM
Room: Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)
Link: https://ash.confex.com/ash/2024/webprogram/Paper206439.html
Details of the poster session:
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I
2074: 1‰ Regular Dose of Metabolically Armored CD19 CAR-T Cells Induces Robust In Vivo Expansion and Complete Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients
Session Time: Saturday, Dec. 7, 2024 5:30 PM - 7:30 PM
Location: Halls G-H (San Diego Convention Center)
Link: https://ash.confex.com/ash/2024/webprogram/Paper207694.html
Meta 10 Technology
Leman Biotech's Metabolic Reprogramming Technology (Meta 10) represents an innovative approach to combating T-cell exhaustion. Preclinical studies have demonstrated its ability to activate oxidative phosphorylation metabolism in terminally exhausted T cells, restoring their proliferative potential and cytotoxic activity. Promising results from these studies include effective tumor clearance in various mouse models and the induction of stem-like immune memory cells.
In early 2023, Leman Biotech initiated an investigator-initiated clinical trial (IIT) for metabolically armed CD19 CAR-T therapy (Meta10-19 CAR-T) targeting patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) and acute B-lymphoblastic leukemia (r/r B-ALL). Remarkably, all patients treated with Meta10-19 CAR-T have achieved complete responses at low doses with minimal side effects. These findings highlight the immense clinical potential of Meta 10 technology.
About Leman Biotech
Leman Biotech is a clinical-stage cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and XtalPi, a leader in AI-driven drug research and development. The company integrates innovative metabolic reprogramming technology with a cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies.
Leman Biotech's core technology, Meta 10, has shown the potential to cure solid tumors, as evidenced by published research in leading academic journals, including Nature Immunology and Nature Biotechnology. The platform is also protected by PCT patents covering major global markets.
The company recently completed a successful angel-plus financing round, raising nearly $18 million, and has plans for further fundraising. Committed to addressing the key challenges in cancer immunotherapy, Leman Biotech aims to improve response rates and efficacy, working tirelessly toward the ultimate goal of curing cancer.
Website: https://www.lemanbio.com/en
